SUPPLEMENTARY DATA

Supplementary Table S1. Simulation to compute the expected rate difference of all-cause death from the LEADER, SUSTAIN-6, EMPA-REG and CANVAS trials of medications to treat type 2 diabetes, expected from the impact of the drugs on the HbA1c reduction in the trials

Trial	Study drug	Sample size	Median follow-up (years)	Mean reduction in HbA1c (%)	Rate difference of all-cause mortality per 1000 PYs		
					Observed	Expected from HbA1c reduction	Residual
LEADER	Liraglutide	9,340	3.8	0.40	-3.7	-1.5	-2.2
SUSTAIN-6	Semaglutide	3,297	2.1	0.85	+0.6	-2.1	+2.7
EMPA-REG	Empagliflozin	7,020	3.1	0.45	-9.2	-1.9	-7.3
CANVAS	Canagliflozin	10,142	2.4	0.58	-2.2	-1.6	-0.6